Trevigen Launches Anti-8-oxo-dG Monoclonal Antibody (Clone 2E2)

Released on: March 4, 2008, 4:30 am

Press Release Author: Belinda De Leon / Trevigen, Inc.

Industry: Biotech

Press Release Summary: DNA damage caused by oxidative radicals is associated with
aging, inflammation, carcinogenesis, Parkinson's and Alzheimer's diseases. When
exposed to oxidative radicals, 8-hydroxy-2'-deoxyguanosine (8-oxo-dG) is formed and
can serve as a sensitive indicator of physiological and environmental damage to DNA.



Press Release Body: DNA damage caused by oxidative radicals is associated with
aging, inflammation, carcinogenesis, Parkinson's and Alzheimer's diseases. When
exposed to oxidative radicals, 8-hydroxy-2'-deoxyguanosine (8-oxo-dG) is formed and
can serve as a sensitive indicator of physiological and environmental damage to DNA.
This mouse monoclonal antibody specifically binds to 8-hydroxy-2'-deoxyguanosine
within DNA in H2O2-treated cells.

It can be used to detect oxidative damage by ELISA and immunocytochemistry. For
optimal outcomes, cells should be grown on a surface that allows for fixation and
direct labeling such as sterile chamber slides and coverslips. This antibody is
provided as purified immunoglobulin from mouse ascites in 1X PBS containing 0.01%
sodium azide.

Sufficient antibody is provided for approximately 50 slides, when a 1:250 dilution
is used (Cat# 4354-MC-050). For details, contact Trevigen by phone at 800-873-8443,
by email info@trevigen.com or visit the website www.trevigen.com.


About Trevigen:
Trevigen is a long standing provider of quality kits and reagents for researchers
investigating programmed cell death, DNA damage and repair, cell differentiation and
angiogenesis. Trevigen recently launched Anti-8-oxo-dG Monoclonal Antibody (Clone
2E2) as part of it DNA Damage product line.


Web Site: http://www.trevigen.com

Contact Details: Press Contact:
Belinda De Leon
800-873-8443
info@trevigen.com
www.trevigen.com
1-800-TREVIGEN

Trevigen, Inc.
8405 Helgerman Ct.
Gaithersburg, MD 20877

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •